Eupraxia Pharmaceuticals Inc faces a challenging trading day as its stock price experiences a notable decline.
Eupraxia Pharmaceuticals Inc (EPRX.TO) is seeing its stock slide by 3.96% in today’s session, closing at CA$8.98. This drop reflects investor concerns amid a lack of recent positive news to support the stock's price.
Advertisement
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$612.11M
52W high
$12.86
52W low
$6.94
1W change
+2.52%
Beta
1.50
Analyst Price Targets
Based on analyst covering EPRX
Wall Street analysts forecast EPRX stock price to rise 71.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.00
+71.1% Upside
Current Price
C$9.35
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
56.0%
Annualized
90-Day Vol
55.7%
Annualized
Trend (90d)
-25.3%
Annualized drift
90d Mean
C$8.54
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.07 | C$7.48 – C$11.01 |
| 60 trading days | C$8.80 | C$6.70 – C$11.57 |
| 90 trading days | C$8.54 | C$6.11 – C$11.94 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: With no significant announcements or developments to boost investor confidence, Eupraxia's stock is struggling in a competitive market, highlighting the need for ongoing monitoring of its performance and news.
Eupraxia Pharmaceuticals Inc down 3.96% today
The market cap of Eupraxia Pharmaceuticals Inc stands at approximately CA$612 million, indicating significant investor interest despite current price pressures.
Bull case
If Eupraxia can effectively utilize its recent public offerings and clinical milestones, it may attract investor interest again and help stabilize its stock price.
Bear case
Ongoing uncertainty and the absence of positive news could lead to further declines, as investors might look for more stable options in the biotech sector.
Market Reaction
Advertisement
The decline in Eupraxia Pharmaceuticals Inc's stock price today can be attributed to a general lack of news that would typically support investor confidence. With no recent announcements or developments, the market is reacting cautiously, resulting in a 3.96% drop.
Investor Sentiment
Investor sentiment seems to be wavering as Eupraxia's stock continues to slide. The lack of positive news or updates on clinical trials may be causing hesitation among current and potential investors, prompting them to reassess their positions in the company.
Looking Ahead
As Eupraxia Pharmaceuticals Inc navigates this challenging period, it will be crucial for the company to provide updates on its clinical trials and financial health. Investors will be closely watching for any signs of recovery or new developments that could influence the stock's trajectory.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
